Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jennifer L. Aldrich is active.

Publication


Featured researches published by Jennifer L. Aldrich.


Clinical and Vaccine Immunology | 2000

Detection of Francisella tularensis in Biological Specimens Using a Capture Enzyme-Linked Immunosorbent Assay, an Immunochromatographic Handheld Assay, and a PCR

Roland Grunow; Wolf D. Splettstoesser; Sahra McDonald; Christian Otterbein; Tom O'Brien; Cecilia Morgan; Jennifer L. Aldrich; Erwin Hofer; Ernst-Jürgen Finke; Hermann Meyer

ABSTRACT The early detection of Francisella tularensis, the causative agent of tularemia, is important for adequate treatment by antibiotics and the outcome of the disease. Here we describe a new capture enzyme-linked immunosorbent assay (cELISA) based on monoclonal antibodies specific for lipopolysaccharide (LPS) of Francisella tularensis subsp. holarctica and Francisella tularensis subsp. tularensis. No cross-reactivity with Francisella tularensis subsp. novicida,Francisella philomiragia, and a panel of other possibly related bacteria, including Brucella spp.,Yersinia spp., Escherichia coli, andBurkholderia spp., was observed. The detection limit of the assay was 103 to 104 bacteria/ml. This sensitivity was achieved by solubilization of the LPS prior to the cELISA. In addition, a novel immunochromatographic membrane-based handheld assay (HHA) and a PCR, targeting sequences of the 17-kDa protein (TUL4) gene of F. tularensis, were used in this study. Compared to the cELISA, the sensitivity of the HHA was about 100 times lower and that of the PCR was about 10 times higher. All three techniques were successfully applied to detect F. tularensis in tissue samples of European brown hares (Lepus europaeus). Whereas all infected samples were recognized by the cELISA, those with relatively low bacterial load were partially or not detected by PCR and HHA, probably due to inhibitors or lack of sensitivity. In conclusion, the HHA can be used as a very fast and simple approach to perform field diagnosis to obtain a first hint of an infection with F. tularensis, especially in emergent situations. In any suspect case, the diagnosis should be confirmed by more sensitive techniques, such as the cELISA and PCR.


International Journal of Medical Microbiology | 2000

Early diagnosis of bubonic plague using F1 antigen capture ELISA assay and rapid immunogold dipstick

Suzanne Chanteau; Lila Rahalison; Mahery Ratsitorahina; Monique Rasolomaharo; Pascal Boisier; Tom O'Brien; Jennifer L. Aldrich; Anne Keleher; Cecilia Morgan; James Burans

Plague is still prevalent in more than 20 countries. Two F1 antigen diagnostic assays (an immunocapture ELISA and an immunogold chromatography dipstick) were evaluated using bubo aspirates, serum and urine specimens from patients suspected with plague. The specificity of the two F1 assays was found 100%. Using bacteriology as a gold reference diagnostic assay, 52 patients were Yersinia pestis culture positive and 141 negative. The sensitivity of the F1 ELISA test was 100% in bubo, 52% in serum and 58% in urine specimens. In culture negative patients, the F1 antigen could be found in 10% bubo aspirates, 5% serum and 7% urine specimens of culture negative patients for whom a seroconversion for anti-F1 antibodies was also observed. The sensitivity of the dipstick assay was 98% on bubo aspirates specimens. Compared to the ELISA test, the agreement rate was 97.5% and the correlation coefficient tau = 0.90 (p < 10(-3)). In conclusion, the diagnosis of bubonic plague has to be performed on bubo fluid rather than on serum or urine specimens. Both the F1 ELISA and the dipstick assays are valuable tools for an early diagnosis and for the surveillance of plague.


Analytical Chemistry | 2003

Multiplexed Liquid Arrays for Simultaneous Detection of Simulants of Biological Warfare Agents

Mary T. McBride; Stuart Gammon; Maurice Pitesky; Tom O'Brien; Thomas W. Smith; Jennifer L. Aldrich; Richard G. Langlois; Bill W. Colston; Kodumudi S. Venkateswaran


Archive | 2001

Anthrax specific antibodies

Beverly L. Mangold; Jennifer L. Aldrich; Tom O'Brien


Archive | 2001

Anthrax-specific antigen, vaccines comprising said antigen, anthrax-specific antibodies, and their uses

Beverly L. Mangold; Jennifer L. Aldrich; Tom O'Brien


Archive | 2005

Spore specific antigen

Beverly L. Mangold; Jennifer L. Aldrich; William M. Nelson


Archive | 2006

Antibodies to a spore specific glycosyl hydrolase

Beverly L. Mangold; Jennifer L. Aldrich; William M. Nelson


Archive | 2005

Bacillus anthracis spore specific antobodies

Beverly L. Mangold; Jennifer L. Aldrich


Archive | 2005

Sporenspezifische antikörper Spore specific antibody

Beverly L. Mangold; Jennifer L. Aldrich


Archive | 2005

Spore specific antibodies

Beverly L. Mangold; Jennifer L. Aldrich

Collaboration


Dive into the Jennifer L. Aldrich's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bill W. Colston

Lawrence Livermore National Laboratory

View shared research outputs
Top Co-Authors

Avatar

Kodumudi S. Venkateswaran

Lawrence Livermore National Laboratory

View shared research outputs
Top Co-Authors

Avatar

Mary T. McBride

Lawrence Livermore National Laboratory

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard G. Langlois

Lawrence Livermore National Laboratory

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lila Rahalison

World Health Organization

View shared research outputs
Researchain Logo
Decentralizing Knowledge